— Shares of biopharmaceutical company AbbVie shed more than 1% after the CEO said at the JPMorgan Healthcare Conference that it expects the loss of exclusivity of Humira, its drug for
arthritis and psoriasis, to affect the company's performance in the near term, according to a report from Bloomberg. The company does not anticipate a decline in 2024 earnings, however.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and moreThese are the stocks posting the largest moves midday.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »
UBS sees these retail stocks winning from a potential Bed Bath & Beyond bankruptcyDoubts about Bed Bath & Beyond's future opens a door for other retailers to pick up market share, says UBS
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »
Bed Bath & Beyond jumps 50% to lead last gasp rally in meme stocks; AMC gains 15%A group of highly speculative stocks rallied double digits on Wednesday as retail investors pushed meme names up again in the new year following a dismal 2022.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »